Overview

A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-189 Tablets and ICP-189 Tablets in Combination with Anti-PD-1 Monoclonal Antibody in Patients with Advanced Solid Tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing InnoCare Pharma Tech Co., Ltd.